Clinical Trial Update: A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating venetoclax with low-dose cytarabine in treatment-naïve acute myeloid leukemia participants has completed, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myelogenous Leukemia, AML | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-29